Table 1.
Demographic, baseline lab, and treatment characteristics in EOT positive viral load patients.
| Patient | Gender | Race | Age | BMI (kg/m2) | INR | Albumin (g/dL) | Total bilirubin (mg/dL) | Platelet (x 1,000/mm3) | ALT (IU/L) | Baseline viral load (IU/mL) | Week 4 viral load (IU/mL) | EOT viral load (IU/mL) | Genotype | Fibrosis level (stage) | Treatment regimen | Previous treatment | SVR 12/24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | Caucasian | 70 | 30 | — | 3.6 | 1 | 312 | 53 | 3,715,090 | Neg | 62 | 1a | 2 | SOF + SIM | Peg-IFN + RBV | Y/Y |
| 2 | F | Caucasian | 62 | 27 | 1.1 | 4.4 | 0.6 | 218 | 77 | 3,895,292 | <15 | 235 | 2b | — | SOF + RBV | — | Y/Y |
| 3 | F | Caucasian | 64 | 32 | — | 3.9 | 0.31 | 189 | 27 | 3,200,000 | Neg | 26 | 1b | 0 | SOF + LED | — | Y/Y |
| 4 | F | Black | 71 | 27 | — | 3.6 | 0.4 | 357 | 35 | 971,341 | Neg | <15 | 1a | — | SOF + LED | — | Y/Y |
| 5∗ | M | Caucasian | 53 | 23 | — | 4 | 0.5 | 183 | 39 | 2,108,530 | Neg | Neg | 1a | — | SOF + LED | Peg-IFN + RBV | Y/Y |
| 6 | M | Caucasian | 29 | 29 | — | 0.3 | 0.3 | 340 | 118 | 1,540,000 | 120 | 28 | 1a | 0 | SOF + LED | — | Y/Y |
| 7 | M | Caucasian | 68 | 30 | 1.2 | 1.1 | 1.1 | 86 | 73 | 3,001,000 | 640 | 62 | 1a | 4 | SOF + LED | — | Y/Y |
| 8 | F | Caucasian | 52 | — | 1.1 | 1.1 | 1.1 | 94 | 82 | 2,300,000 | 206 | 18 | 1a | 4 | SOF + VEL + VOX | Peg-IFN + RBV SOF + LED | Y/Y |
| 9 | F | Caucasian | 62 | — | 0.9 | 0.4 | 0.4 | 239 | 157 | 2,108,530 | 128 | 14 | 1a | 2 | GLE + PIB | — | Y/Y |
∗Patients had a negative EOT viral load, but 23 IU/mL at week four after EOT. Abbreviations: SOF, sofosbuvir; SIM, simeprevir; peg-IFN, pegylated interferon; RBV, ribavirin; LED, ledipasvir; VEL, velpatasvir; VOX, voxilaprevir; GLE, glecaprevir; PIB, pibrentasavir.